High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements

specific

High-grade B-cell lymphoma characterized by the abnormal rearrangement of MYC gene, BCL2 gene, and BCL6 gene. Patients with this type of lymphoma usually respond poorly to standard treatments and have a poor prognosis.

30

Centers

1

Active Trials

Cancer Funding

Top Centers for High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements(30)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
High-Volume Research Center
73.4
2
NCI Comprehensive
50.9
3
NCI Comprehensive
50.9
4
NCI Comprehensive
50.9
5
NCI Comprehensive
50.9
6
NCI Comprehensive
50.9
750.9
850.9
9
NCI Comprehensive
50.9
1050.9
11
NCI Comprehensive
50.9
12
NCI Comprehensive
50.9
13
NCI Comprehensive
50.9
14
NCI Comprehensive
50.9
15
NCI Comprehensive
50.9
1650.9
17
NCI Comprehensive
50.9
18
Cedars-Sinai CancerLos Angeles, CA
50.9
19
NCI Comprehensive
50.9
2050.9
2150.9
22
Rutgers Cancer InstituteNew Brunswick, NJ
NCI Comprehensive
50.9
2350.9
2450.9
2550.9
2650.9
2750.9
2850.9
2950.9
3050.9

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →